ION537 / Ionis, UT MD Anderson Cancer Center - LARVOL DELTA

Hippo/YAP signaling pathway in colorectal cancer: regulatory mechanisms and potential drug exploration. (PubMed, Front Oncol) - "Preclinical and clinical investigations highlight the efficacy of diverse Hippo/YAP-targeted interventions, with recent clinical trials (e.g., VT3989, IK-930, IAG933, ION537) underscoring the translational promise of this pathway. Integrating cutting-edge insights into its regulatory networks and clinical targeting offers novel perspectives for precision oncology. By bridging fundamental discoveries with translational applications, this review establishes Hippo/YAP as a compelling therapeutic target and provides a theoretical foundation for developing innovative CRC therapies."

Journal • Review • CNS Disorders • Colorectal Cancer • Oncology • Psychiatry • Solid Tumor • TAFAZZIN

A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: Ionis Pharmaceuticals, Inc. | Recruiting ➔ Completed | N=102 ➔ 15 | Trial completion date: Jun 2023 ➔ Oct 2022 | Trial primary completion date: Jun 2023 ➔ Oct 2022

Enrollment change • Metastases • Trial completion • Trial completion date • Trial primary completion date • Oncology • Prostate Cancer • Solid Tumor • YAP1